Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

New

Multiple Sclerosis Therapies Market by Type (Immunosuppressants and Immunomodulators) and Route of Administration (Oral, Injectable, and Intravenous): Global Opportunity Analysis and Industry Forecast, 2019–2026

A01119
Pages: 151
May 2020 | 5011 Views
 
Author(s) : Snehal Manjrekar, and Onkar Sumant
Tables: 75
Charts: 37
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Multiple Sclerosis Therapies Market

Request Now !

The global multiple sclerosis (MS) therapies market was valued at $22.99 billion in 2018, and is projected to reach $28.00 billion by 2026, registering a CAGR of 2.5% from 2019 to 2026. Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the central nervous system and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual suffering from severe MS experiences speech and movement problems. Multiple sclerosis can be broadly classified into four types, RRMS, SPMS, PPMS, and PRMS. 

Updated_MS-Therapies-Market,-2019-2026

Get more information on this report : Request Sample Pages

One of the major challenges in the global MS therapies market is the unknown etiology of the disease. Thus, it is difficult for medical researchers to develop drugs that target the key source of the disease. However, the introduction of disease-modifying drugs as a treatment option is a key factor that drives the growth of the global MS therapies market. In addition, the growth of the global MS therapies market is driven by shift in preference toward oral drugs. For example, drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis. Moreover, increase in number of pipeline drugs is anticipated to offer remunerative opportunities for market expansion during the forecast period. Daclizumab, RG1594 (Ocrelizumab), and Lemtrada (Alemtuzumab) are the novel late stage pipeline products likely to enter the market during the forecast period. The launch of new pipeline products is expected to change the present market scenario, which is dependent on injectable formulations (such as Avonex, Betaseron/Betaferon, Rebif, Copaxone, and Tysabri). These drugs need to be injected frequently, and their dose frequency ranges from daily to weekly administration. Some of the new drugs are oral formulations (Aubagio and BG-12) while others are injectable formulations (Daclizumab, Ocrelizumab, and Alemtuzumab), and all require dosing either once a month or once every six months. Therefore, these drugs are expected to be well-tolerated and improve patient compliance. In addition, the price of these products is expected to be lower than the price of the current products. Some of these products have shown superior efficacy (BG-12 and Lamtrada) in clinical trials compared with the currently approved products (Copaxone and Rebif).

Type Segment Review

On the basis of type, the market is classified into immunosuppressants and immunomodulators. The immunosuppressants segment was the highest contributor to the market, owing to their beneficial effects for patients suffering from relapsing-remitting multiple sclerosis (RRMS) by weakening the immune system, thereby suppressing the autoimmune attack in the patient’s body and preventing relapses. In addition, the increase in product approvals for the treatment of MS therapies is anticipated to propel the market growth globally. Currently, the immunosuppressants that have been approved for use only in relapsing forms of MS, include alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta preparations, natalizumab, ocrelizumab, and teriflunomide.

Multiple Sclerosis Therapies Market
By Type

Your browser does not support the canvas element.

Immunosuppressants segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Route of Administration Segment Review

Depending on route of administration, the market is divided into oral, injectable, and intravenous. The oral route of administration promotes patient satisfaction and increases therapeutic compliance. Significant therapeutic advances in the new orally administered drugs approved for the MS treatment represent boost the growth of the market. Three oral drugs have been approved by regulatory agencies for the treatment of MS, which include fingolimod, teriflunomide, and dimethyl fumarate. The mechanisms of action, efficacy, and safety of these drugs that have yielded positive results in phase III trials, which is a key factor that contributes toward the growth of the global market.

Multiple Sclerosis Therapies Market
By Route of Administration

Your browser does not support the canvas element.

The Oral route of administration segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Region segment review

North America accounted for the largest share in the global MS therapies market in 2018, owing to increase in demand for MS therapeutic products. In addition, the factors that boost the growth of the MS therapies market in North America include easy availability of MS therapies and increase favorable reimbursement policies by government for MS treatment. Moreover, the presence of key players such as Pfizer, Novartis, and Bayer in the region contributes to the growth of market. Furthermore, it has been observed that rates of MS are higher in regions further from equator; thus, the prevalence of MS is alarmingly high in North America. For instance, according to the Government of Canada, in 2014-15, approximately 77,000 people were suffering from MS. In addition, according to the Global Burden of Disease Study, 2016, North America accounted for highest age-standardized MS prevalence at 164.6 per 100,000 population. Therefore, rise in prevalence has led to surge in demand for MS therapies in the region, thereby fueling the growth of the market. 

Multiple Sclerosis Therapies Market
By Region

2026
North America 
Europe
Asia-pacific
Lamea

North America accounted for the largest share in the MS therapies market in 2018, and is anticipated to remain dominant throughout the forecast period.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current MS therapies market trends and forecast estimations from 2019 to 2027, which assists to identify the prevailing market opportunities. 

  • An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.

  • A comprehensive analysis of factors that drive and restrain the growth of the global is provided.

  • Region-wise and country-wise market conditions are comprehensively analyzed in this report.

  • The projections in this report are made by analyzing the current trends and future market potential from 2019 to 2026, in terms of value.

  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.

  • Key market players within the MS therapies market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global MS therapies market.

Key Market Segments

By Type 

  • Immunosuppressants
  • Immunomodulators

By Route Of Administration

  • Oral
  • Injectable
  • Intravenous  

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Spain
    • Italy
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Market dynamics

3.3.1.Drivers

3.3.1.1.Increase in number of pipeline drugs
3.3.1.2.Upsurge in patient population
3.3.1.3.Surge in number of patient assistance programs (PAPs )

3.3.2.Restraint

3.3.2.1.Unspecified etiology of the disease

3.3.3.Opportunities

3.3.3.1.Introduction of disease-modifying drugs
3.3.3.2.Use of off-label drugs

CHAPTER 4:MS THERAPIES MARKET, BY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Immunosuppressants

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Immunomodulators

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

CHAPTER 5:MS THERAPIES MARKET, BY ROUTE OF ADMINISTRATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Oral

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Injectable

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Intravenous

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:MS THERAPIES MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends and opportunities
6.2.2.Market analysis by country

6.2.2.1.U.S.

6.2.2.1.1.U.S. market size and forecast, by type
6.2.2.1.2.U.S. market size and forecast, by route of administration

6.2.2.2.Canada

6.2.2.2.1.Canada market size and forecast, by type
6.2.2.2.2.Canada market size and forecast, by route of administration

6.2.2.3.Mexico

6.2.2.3.1.Mexico market size and forecast, by type
6.2.2.3.2.Mexico market size and forecast, by route of administration

6.3.Europe

6.3.1.Key market trends and opportunities
6.3.2.Market analysis by country

6.3.2.1.UK

6.3.2.1.1.UK market size and forecast, by type
6.3.2.1.2.UK market size and forecast, by route of administration

6.3.2.2.Germany

6.3.2.2.1.Germany market size and forecast, by type
6.3.2.2.2.Germany market size and forecast, by route of administration

6.3.2.3.France

6.3.2.3.1.France market size and forecast, by type
6.3.2.3.2.France market size and forecast, by route of administration

6.3.2.5.Italy
 

6.3.2.5.1.Italy market size and forecast, by type
6.3.2.5.2.Italy market size and forecast, by route of administration

6.3.2.6.Spain

6.3.2.6.1.Spain market size and forecast, by type
6.3.2.6.2.Spain market size and forecast, by route of administration

6.3.2.7.Rest of Europe

6.3.2.7.1.Rest of Europe market size and forecast, by type
6.3.2.7.2.Rest of Europe market size and forecast, by route of administration

6.4.Asia-Pacific

6.4.1.Key market trends and opportunities
6.4.2.Market analysis by country

6.4.2.1.Japan

6.4.2.1.1.Japan market size and forecast, by type
6.4.2.1.2.Japan market size and forecast, by route of administration

6.4.2.2.China

6.4.2.2.1.China market size and forecast, by type
6.4.2.2.2.China market size and forecast, by route of administration

6.4.2.3.Australia

6.4.2.3.1.Australia market size and forecast, by type
6.4.2.3.2.Australia market size and forecast, by route of administration

6.4.2.4.India

6.4.2.4.1.India market size and forecast, by type
6.4.2.4.2.India market size and forecast, by route of administration

6.4.2.5.Rest of Asia-Pacific

6.4.2.5.1.Rest of Asia-Pacific market size and forecast, by type
6.4.2.5.2.Rest of Asia-Pacific market size and forecast, by route of administration

6.5.LAMEA

6.5.1.Key market trends and opportunities
6.5.2.Market analysis by country

6.5.2.1.Brazil

6.5.2.1.1.Brazil market size and forecast, by type
6.5.2.1.2.Brazil market size and forecast, by route of administration

6.5.2.2.South Africa6.5.2.2.1.South Africa market size and forecast, by type
 

6.5.2.2.2.South Africa market size and forecast, by route of administration

6.5.2.3.Saudi Arabia

6.5.2.3.1.Saudi Arabia market size and forecast, by type
6.5.2.3.2.Saudi Arabia market size and forecast, by route of administration

6.5.2.4.Rest of LAMEA

6.5.2.4.1.Rest of LAMEA market size and forecast, by type
6.5.2.4.2.Rest of LAMEA market size and forecast, by route of administration

CHAPTER 7:COMPANY PROFILES

7.1.ABBVIE INC.

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.BAYER AG.

7.2.1.Company overview
7.2.2.Operating business segments
7.2.3.Product portfolio
7.2.4.Business performance

7.3.BIOGEN

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments

7.4.BRISTOL-MYERS SQUIBB COMPANY

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.F. HOFFMANN-LA ROCHE LTD.

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Business performance
7.5.5.Key strategic moves and developments

7.6.MERCK KGAA

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance

7.7.NOVARTIS AG.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments

7.8.PFIZER INC.

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance

7.9.SANOFI

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance

7.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL MS THERAPIES MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 02.IMMUNOSUPPRESSANTS MS THERAPIES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03.IMMUNOMODULATORS MS THERAPIES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04.GLOBAL MS THERAPIES MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 05.MS THERAPIES MARKET FOR ORAL, BY REGION, 2018–2026 ($MILLION)
TABLE 06.INJECTABLE MS THERAPIES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07.MS THERAPIES MARKET FOR INTRAVENOUS, BY REGION, 2018–2026 ($MILLION)
TABLE 08.MS THERAPIES MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 09.NORTH AMERICA MS THERAPIES MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)
TABLE 10.U.S. MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 11.U.S. MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 12.CANADA MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 13.CANADA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 14.MEXICO MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 15.MEXICO MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 16.EUROPE MS THERAPIES MARKET REVENUE, BY COUNTRY 2018–2026 ($MILLION)
TABLE 17.UK MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 18.UK MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 19.GERMANY MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 20.GERMANY MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 21.FRANCE MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 22.FRANCE MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 23.ITALY MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 24.ITALY MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 25.SPAIN MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 26.SPAIN MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 27.REST OF EUROPE MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 28.REST OF EUROPE MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 29.ASIA-PACIFIC MS THERAPIES MARKET REVENUE, BY COUNTRY 2018–2026 ($MILLION)
TABLE 30.JAPAN MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 31.JAPAN MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 32.CHINA MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 33.CHINA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 34.AUSTRALIA MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 35.AUSTRALIA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 36.INDIA MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 37.INDIA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 38.REST OF ASIA-PACIFIC MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 39.REST OF ASIA-PACIFIC MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 40.LAMEA MS THERAPIES MARKET REVENUE, BY COUNTRY 2018–2026 ($MILLION)
TABLE 41.BRAZIL MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 42.BRAZIL MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 43.SOUTH AFRICA MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 44.SOUTH AFRICA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 45.SAUDI ARABIA MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 46.SAUDI ARABIA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 47.REST OF LAMEA MS THERAPIES MARKET REVENUE, BY TYPE 2018–2026 ($MILLION)
TABLE 48.REST OF LAMEA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 49.ABBVIE: COMPANY SNAPSHOT
TABLE 50.ABBVIE: OPERATING BUSINESS SEGMENTS
TABLE 51.ABBVIE: PRODUCT PORTFOLIO
TABLE 52.BAYER.: COMPANY SNAPSHOT
TABLE 53.BAYER.: OPERATING SEGMENTS
TABLE 54.BAYER.: PRODUCT PORTFOLIO
TABLE 55.BIOGEN: COMPANY SNAPSHOT
TABLE 56.AMGEN: PRODUCT PORTFOLIO
TABLE 57.BMS: COMPANY SNAPSHOT
TABLE 58.BMS: OPERATING SEGMENTS
TABLE 59.BMS: PRODUCT PORTFOLIO
TABLE 60.ROCHE: COMPANY SNAPSHOT
TABLE 61.ROCHE: OPERATING SEGMENTS
TABLE 62.MERCK: COMPANY SNAPSHOT
TABLE 63.MERCK: OPERATING BUSINESS SEGMENTS
TABLE 64.MERCK: PRODUCT PORTFOLIO
TABLE 65.NOVARTIS: COMPANY SNAPSHOT
TABLE 66.NOVARTIS: OPERATING SEGMENTS
TABLE 67.NOVARTIS: PRODUCT PORTFOLIO
TABLE 68.PFIZER: COMPANY SNAPSHOT
TABLE 69.PFIZER: OPERATING SEGMENTS
TABLE 70.PFIZER: PRODUCT PORTFOLIO
TABLE 71.SANOFI: COMPANY SNAPSHOT
TABLE 72.SANOFI: OPERATING SEGMENTS
TABLE 73.SANOFI: PRODUCT PORTFOLIO
TABLE 74.TEVA: COMPANY SNAPSHOT
TABLE 75.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL MS THERAPIES DEVICES MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2016–2019*
FIGURE 04.TOP WINNING STRATEGIES, BY COMPANY, 2016–2019*
FIGURE 05.TOP IMPACTING FACTORS
FIGURE 06.DRUGS IN DEVELOPMENT, 2019
FIGURE 07.COMPARATIVE ANALYSIS OF IMMUNOSUPPRESSANTS MS THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
FIGURE 08.COMPARATIVE ANALYSIS OF IMMUNOMODULATORS MS THERAPIES MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 09.ORAL MS THERAPIES MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 10.MS THERAPIES MARKET FOR INJECTABLE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11.MS THERAPIES MARKET FOR INTRAVENOUS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12.ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 13.ABBVIE: REVENUE SALESBY SEGMENT,2018 (%)
FIGURE 14.ABBVIE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 15.BAYER: NET SALES, 2016–2018 ($MILLION)
FIGURE 16.BAYER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 17.BAYER: REVENUE SHARE BY REGION, 2018(%)
FIGURE 18.BIOGEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 19.BMS: NET SALES, 2016–2018 ($MILLION)
FIGURE 20.BMS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 21.ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 22.ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 23.ROCHE: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 24.MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 25.MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 26.MERCK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 27.NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 28.NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 29.NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 30.PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 31.PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 32.PFIZER: REVENUE SHARE BY REGION, 2018(%)
FIGURE 33.SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 34.SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 35.SANOFI: REVENUE SHARE BY REGION, 2018(%)
FIGURE 36.TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 37.TEVA: REVENUE SHARE BY REGION, 2018(%)

 
 

The MS therapies market is expected to witness significant growth, owing to increase in incidence of multiple sclerosis (MS) worldwide. MS is a condition caused due to myelin damage that disrupts the impulse communication between the brain and rest of the body. MS is highly prevalent among women between the ages of 20 and 50 years.

According to the CXOs, increase in initiatives from the government to offer favorable reimbursements, rise in the number of R&D activities to develop novel medications for MS, and increase in incidence of MS are major factors responsible for the growth of the market. Moreover, pharmaceutical companies are targeting the Asia-Pacific region to commercialize drugs at affordable pricing. This is expected to provide a competitive advantage for the Asia-Pacific MS drugs market. However, the side effects associated with therapeutics and high cost of drugs are expected limit the market growth.

On the contrary, pharmaceutical companies in developed regions are focusing on the commercialization of novel therapeutics having minimal side effects and economic pricing. Such product launch strategy is expected to offer lucrative opportunity for market expansion during the forecast period. Furthermore, the market growth is majorly supplemented by increase in funding from government authorities for R&D activities.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subscription @ $699 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total market value of MS Therapies market is $28 billion

A. The forecast period in the report is from 2019 to 2026

A. The market value of MS Therapies market in 2019 was $23.57 billion

A. The base year for the report is 2018

A. Yes, MS Therapies companies are profiled in the report

A. The top companies that hold the market share in MS Therapies market are Abbvie Inc., Bayer AG, Biogen, BristolMyers Squibb Company, F. Hoffmann-La Roche Ltd., Merck KGaA.

A. The top 5 emerging investments markets in the MS Therapies market are Canada, UK, Australia, Germany and France.

A. The key trends in the MS Therapies market are introduction of novel drugs to treat multiple sclerosis and alarming increase in patient base suffering from MS.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Multiple Sclerosis Therapies Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $0.00
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts